These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2253664)

  • 1. Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms.
    Hildebrand M; Staks T; Nieuweboer B
    Eur J Clin Pharmacol; 1990; 39(2):149-53. PubMed ID: 2253664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
    Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
    Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 3H-cicaprost in healthy volunteers.
    Hildebrand M; Staks T; Schütt A; Matthes H
    Prostaglandins; 1989 Feb; 37(2):259-73. PubMed ID: 2657866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers.
    Demolis JL; Robert A; Mouren M; Funck-Brentano C; Jaillon P
    J Cardiovasc Pharmacol; 1993 Nov; 22(5):711-6. PubMed ID: 7506323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study.
    Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ
    Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers.
    Uematsu T; Umemura K; Nakano M; Kosuge K; Nakashima M
    Int J Clin Pharmacol Ther Toxicol; 1993 Aug; 31(8):373-5. PubMed ID: 8225681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects.
    Nony P; Ffrench P; Girard P; Delair S; Azoulay S; Girre JP; Dechavanne M; Boissel JP
    Can J Physiol Pharmacol; 1996 Aug; 74(8):887-93. PubMed ID: 8960377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.
    Hildebrand M
    Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia.
    Hohlfeld T; Weber A; Schrör K
    Agents Actions Suppl; 1992; 37():289-96. PubMed ID: 1632303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of iloprost and cicaprost in mice.
    Hildebrand M
    Prostaglandins; 1992 Nov; 44(5):431-42. PubMed ID: 1281921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivation of eptaloprost in animals and man.
    Hildebrand M
    Prostaglandins; 1993 Aug; 46(2):177-89. PubMed ID: 7692471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo anti-platelet effects of isocarbacyclin methyl ester incorporated in lipid microspheres in rabbits.
    Inoue K; Aoki Y; Hayashi M; Kitahara S; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):980-4. PubMed ID: 7488317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.
    Cushing DJ; Souney PF; Cooper WD; Mosher GL; Adams MP; Machatha S; Zhang B; Kowey PR
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):3-8. PubMed ID: 21933229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.
    Krause W; Krais T
    Eur J Clin Pharmacol; 1987; 32(6):597-605. PubMed ID: 2443364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.
    Warot D; Berlin I; Aymard G; Ankri A; Fabry C; Besse B; Lechat P; Diquet B
    Fundam Clin Pharmacol; 2000; 14(3):231-6. PubMed ID: 15602800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma.
    Schirner M; Schneider MR
    J Cancer Res Clin Oncol; 1992; 118(7):497-501. PubMed ID: 1624541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
    Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.